Biogen Stock Forecast, Price & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BIIB stock has decreased by 9.2% and is now trading at $267.12.
View which stocks have been most impacted by COVID-19.

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 4 sell ratings, 16 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Biogen.

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, October 21st 2020.
View our earnings forecast for Biogen.

Biogen will be holding an earnings conference call on Wednesday, October 21st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Biogen Inc. (NASDAQ:BIIB) released its quarterly earnings results on Wednesday, July, 22nd. The biotechnology company reported $10.26 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $8.03 by $2.23. The biotechnology company had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.44 billion. Biogen had a net margin of 40.91% and a return on equity of 50.10%. During the same quarter last year, the company posted $9.15 earnings per share.
View Biogen's earnings history.

Biogen declared that its board has approved a stock buyback plan on Monday, December 23rd 2019, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its stock is undervalued.

Biogen updated its FY20 earnings guidance on Wednesday, July, 22nd. The company provided earnings per share guidance of $34.00-36.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $31.98. The company issued revenue guidance of $13.8-14.2 billion, compared to the consensus revenue estimate of $13.90 billion.

31 equities research analysts have issued 12-month price targets for Biogen's shares. Their forecasts range from $228.00 to $396.00. On average, they expect Biogen's share price to reach $311.82 in the next year. This suggests a possible upside of 16.7% from the stock's current price.
View analysts' price targets for Biogen.

Biogen saw a decrease in short interest in the month of September. As of September 30th, there was short interest totaling 2,830,000 shares, a decrease of 23.3% from the September 15th total of 3,690,000 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is presently 2.5 days. Currently, 1.8% of the shares of the stock are sold short.
View Biogen's Short Interest.

Some companies that are related to Biogen include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN) and Exelixis (EXEL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by many different institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.23%), DNB Asset Management AS (0.16%), Saratoga Research & Investment Management (0.15%), PGGM Investments (0.12%), Envestnet Asset Management Inc. (0.12%) and Assenagon Asset Management S.A. (0.08%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin.
View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Wedge Capital Management L L P NC, Gateway Investment Advisers LLC, Factory Mutual Insurance Co., Hexavest Inc., Redpoint Investment Management Pty Ltd, Bowling Portfolio Management LLC, and Nissay Asset Management Corp Japan ADV. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin.
View insider buying and selling activity for Biogen.

BIIB stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, State of Alaska Department of Revenue, Candriam Luxembourg S.C.A., 6 Meridian, Denali Advisors LLC, Rhenman & Partners Asset Management AB, Envestnet Asset Management Inc., and Nisa Investment Advisors LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $267.12.

Biogen has a market capitalization of $42.29 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

The official website for Biogen is www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]